Loading
Early plasma-cell conditions with no organ damage; most never progress, but high-risk smouldering disease is now sometimes treated.
MGUS progresses at ~1% per year; smouldering myeloma at ~10% per year for five years, higher with the 20/2/20 criteria (M-protein >2 g/dL, >20% plasma cells, free light chain ratio >20). Lenalidomide (E3A06) and daratumumab (AQUILA, 2024: progression HR 0.49) delay progression in high-risk smouldering disease; whether to treat remains debated. iStopMM (Iceland) is screening a whole population.
Showing the molecule this term concerns: Lenalidomide.
Shares iStopMM, Multiple myeloma.
Shares Smouldering multiple myeloma, Daratumumab, Multiple myeloma.
Shares M-protein, immunofixation and serum free light chains, Smouldering multiple myeloma, Multiple myeloma.
Shares Smouldering multiple myeloma, Lenalidomide.
Shares Smouldering multiple myeloma, Daratumumab, Multiple myeloma.
Shares Daratumumab, Lenalidomide, Multiple myeloma.
Shares Daratumumab, Lenalidomide, Multiple myeloma.
Shares Smouldering multiple myeloma, Lenalidomide, Multiple myeloma.